INmune Bio, Inc.
INMB
$1.98
-$0.03-1.49%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 50.00K | 50.00K | 14.00K | 42.00K | 85.00K |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 50.00K | 50.00K | 14.00K | 42.00K | 85.00K |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | 50.00K | 50.00K | 14.00K | 42.00K | 85.00K |
| SG&A Expenses | 8.90M | 9.46M | 9.48M | 9.77M | 10.14M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 39.77M | 41.57M | 42.65M | 41.59M | 37.87M |
| Operating Income | -39.72M | -41.52M | -42.64M | -41.55M | -37.79M |
| Income Before Tax | -55.51M | -40.80M | -42.08M | -41.27M | -37.74M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -55.51 | -40.80 | -42.08 | -41.27 | -37.74 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -55.51M | -40.80M | -42.08M | -41.27M | -37.74M |
| EBIT | -39.72M | -41.52M | -42.64M | -41.55M | -37.79M |
| EBITDA | -- | -- | -- | -- | -- |
| EPS Basic | -2.50 | -1.95 | -2.13 | -2.18 | -2.06 |
| Normalized Basic EPS | -1.12 | -1.22 | -1.33 | -1.36 | -1.29 |
| EPS Diluted | -2.50 | -1.95 | -2.13 | -2.18 | -2.06 |
| Normalized Diluted EPS | -1.12 | -1.22 | -1.33 | -1.36 | -1.29 |
| Average Basic Shares Outstanding | 88.23M | 84.24M | 79.77M | 75.54M | 73.36M |
| Average Diluted Shares Outstanding | 88.23M | 84.24M | 79.77M | 75.54M | 73.36M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |